ALUR vs. OM, MODD, NXL, BDMD, CLGN, MBOT, TMDIF, MDAI, NMTC, and FEMY
Should you be buying Allurion Technologies stock or one of its competitors? The main competitors of Allurion Technologies include Outset Medical (OM), Modular Medical (MODD), Nexalin Technology (NXL), Baird Medical Investment (BDMD), CollPlant Biotechnologies (CLGN), Microbot Medical (MBOT), Titan Medical (TMDIF), Spectral AI (MDAI), NeuroOne Medical Technologies (NMTC), and Femasys (FEMY). These companies are all part of the "medical equipment" industry.
Allurion Technologies vs.
Allurion Technologies (NYSE:ALUR) and Outset Medical (NASDAQ:OM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, community ranking, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.
Allurion Technologies presently has a consensus price target of $54.17, indicating a potential upside of 1,425.82%. Outset Medical has a consensus price target of $4.50, indicating a potential upside of 414.05%. Given Allurion Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Allurion Technologies is more favorable than Outset Medical.
In the previous week, Outset Medical had 13 more articles in the media than Allurion Technologies. MarketBeat recorded 18 mentions for Outset Medical and 5 mentions for Allurion Technologies. Allurion Technologies' average media sentiment score of 0.11 beat Outset Medical's score of -0.16 indicating that Allurion Technologies is being referred to more favorably in the media.
Outset Medical received 17 more outperform votes than Allurion Technologies when rated by MarketBeat users. However, 87.50% of users gave Allurion Technologies an outperform vote while only 38.71% of users gave Outset Medical an outperform vote.
Allurion Technologies has a beta of -0.69, suggesting that its stock price is 169% less volatile than the S&P 500. Comparatively, Outset Medical has a beta of 2.01, suggesting that its stock price is 101% more volatile than the S&P 500.
21.4% of Allurion Technologies shares are owned by institutional investors. 22.4% of Allurion Technologies shares are owned by company insiders. Comparatively, 4.1% of Outset Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Allurion Technologies has higher earnings, but lower revenue than Outset Medical. Outset Medical is trading at a lower price-to-earnings ratio than Allurion Technologies, indicating that it is currently the more affordable of the two stocks.
Allurion Technologies has a net margin of -71.24% compared to Outset Medical's net margin of -112.57%. Allurion Technologies' return on equity of 0.00% beat Outset Medical's return on equity.
Summary
Allurion Technologies beats Outset Medical on 11 of the 19 factors compared between the two stocks.
Get Allurion Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALUR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Allurion Technologies Competitors List
Related Companies and Tools
This page (NYSE:ALUR) was last updated on 2/21/2025 by MarketBeat.com Staff
